Modern cardiology has given up on curing heart disease. Its aggressive interventions-- coronary artery bypass graft, atherectomy, angioplasty, and stenting--do not reduce the frequency of new heart attacks or prolong survival except in small subsets of pa
An unreasonable gap exists between medical enthusiasm devoted to acute interventions and meager efforts devoted to secondary prevention. Rene C. Favaloro, MD, Pioneer of Coronary Artery Bypass Graft Surgery
elective PTCA of totally occluded coronary arteries is feasible but the primary success rate is lower (57%) than that associated with conventional lesions. The long-term clinical results following successful angioplasty are satisfactory (64%), but the inc
Our patient exemplified the challenges involved in a CTO, which included the length of the lesion, the lack of a proximal nipple, the presence of a side branch at the occlusion point, poor visualization of the distal vessel despite contralateral injection
Human resolvin E1 inhibits both the migration of inflammatory cells to sites of inflammation and the turning on of other inflammatory cells. Aspirin-triggered resolivins are made from omega-3 fatty acids by cellular enzymes. COX-2 inhibitors also inhibit
Drug-eluting stents (DES) have gained widespread adoption being implanted in over 6 million patients worldwide demonstrating significant improvements in clinical efficacy combined with comparable safety to bare metal stents.
An investigational drug-eluting stent called Xience, coated with everolimus, led to significantly less late lumen loss after nine months than did the Taxus (paclitaxel-eluting) stent, said researchers here today. March 2007
An investigational bioabsorbable coronary artery stent, in its first human trials, showed acceptable safety, with efficacy better than bare-metal devices but well short of drug-eluting devices, Dutch researchers said here.
Martin Leon, M.D., a leading interventional cardiologist accused of leaking details of a major study weeks before its scheduled release, was barred today from taking part in next year's American College of Cardiology meeting.
An investigational bioabsorbable magnesium coronary stent worked as advertised for several months but led to a higher revascularization rate at one year.